In Brief
An antibody that targets a prostate cell protein shows potential for designing safer, more effective prostate cancer therapies.
In the Lab
An antibody that targets a protein specific to prostate cells can be used to image prostate cancer more clearly and indicate how well drugs are working.
In the Clinic
Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.
